JPS5029716A - - Google Patents
Info
- Publication number
- JPS5029716A JPS5029716A JP49053962A JP5396274A JPS5029716A JP S5029716 A JPS5029716 A JP S5029716A JP 49053962 A JP49053962 A JP 49053962A JP 5396274 A JP5396274 A JP 5396274A JP S5029716 A JPS5029716 A JP S5029716A
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7306960A SE7306960L (enExample) | 1973-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS5029716A true JPS5029716A (enExample) | 1975-03-25 |
Family
ID=20317502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP49053962A Pending JPS5029716A (enExample) | 1973-05-17 | 1974-05-16 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US3961060A (enExample) |
| JP (1) | JPS5029716A (enExample) |
| AU (1) | AU6889274A (enExample) |
| DE (1) | DE2423529A1 (enExample) |
| FI (1) | FI152074A7 (enExample) |
| FR (1) | FR2229412A1 (enExample) |
| NL (1) | NL7406689A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501888A (ja) * | 2000-06-23 | 2004-01-22 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | ホスホジエステラーゼｉｖ阻害活性を有する薬剤の調製に有用な化合物 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2856393C2 (de) * | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| JPS5852219A (ja) * | 1981-09-22 | 1983-03-28 | Sumitomo Chem Co Ltd | パ−キンソン病治療剤 |
| US4663349A (en) * | 1985-12-30 | 1987-05-05 | Merck & Co., Inc. | Rectally absorbable form of L-dopa |
| US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
| US5753712A (en) * | 1994-02-18 | 1998-05-19 | Pinsker; Walter | Treatment of migraine headaches and formulations |
| US5786360A (en) | 1996-11-19 | 1998-07-28 | Link Technology Incorporated | A1 adenosine receptor antagonists |
| US5945424A (en) * | 1998-07-31 | 1999-08-31 | G & H Associates, Inc. | Treatment of periodic limb movement syndrome |
| WO2001032170A1 (en) * | 1999-09-13 | 2001-05-10 | Swope David M | Composition and method for decreasing neurologic symptomatology |
| CA2410531A1 (en) * | 2000-05-24 | 2001-11-29 | Eli Lilly And Company | Combination therapy for treatment of depression |
| US20030092770A1 (en) * | 2002-10-23 | 2003-05-15 | Phil Skolnick | Combination therapy for treatment of depression |
| US8338420B1 (en) | 2002-12-04 | 2012-12-25 | Mitsubishi Tanabe Pharma Corporation | Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor |
| WO2004074247A2 (en) | 2003-02-19 | 2004-09-02 | Endacea, Inc. | A1 adenosine receptor antagonists |
| WO2004082624A2 (en) * | 2003-03-17 | 2004-09-30 | Neurohealing Pharmaceuticals, Inc. | Modafinil-based neurorehabilitation of impaired neurological function associated with injury |
| US7943632B2 (en) * | 2003-03-17 | 2011-05-17 | Neurohealing Pharmaceuticals, Inc. | High potency dopaminergic treatment of neurological impairment associated with brain injury |
| EP1636229A4 (en) * | 2003-06-06 | 2008-07-30 | Endacea Inc | ADENOSINE A1 RECEPTOR ANTAGONISTS |
| EP1636230A4 (en) * | 2003-06-09 | 2010-06-16 | Endacea Inc | ADENOSINE A1 RECEPTOR ANTAGONISTS |
| US9364474B2 (en) | 2004-09-20 | 2016-06-14 | Meddev Inc. | Method for treatment of neurologic dysfunction |
| US7645766B1 (en) * | 2004-09-20 | 2010-01-12 | MedDEV, Inc. | Method for treatment of depression and depressive mood disorders |
| US8440685B1 (en) | 2004-09-20 | 2013-05-14 | MedDEV, Inc. | Method for treatment of neurologic dysfunction |
| ES2627655T3 (es) * | 2009-05-19 | 2017-07-31 | Neuroderm Ltd | Composiciones para la administración continua de inhibidores de DOPA descarboxilasa |
| WO2013016662A1 (en) * | 2011-07-28 | 2013-01-31 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| HK1219416A1 (zh) | 2013-03-08 | 2017-04-07 | Benjamin M. YU | 以溶液或悬浮液的形式透皮传输咖啡因的方法和成分 |
| AU2015229521A1 (en) | 2014-03-10 | 2016-09-01 | Benjamin M. YU | Methods and compositions for transdermal delivery |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| PT3116475T (pt) | 2014-03-13 | 2020-12-15 | Neuroderm Ltd | Composições de inibidores de dopa-descarboxilase |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3646213A (en) * | 1970-08-12 | 1972-02-29 | Hoffmann La Roche | Compositions and methods for treating depression with combinations of l-3 4-dihydroxyphenylalanine and a hydrazine |
-
1974
- 1974-05-14 AU AU68892/74A patent/AU6889274A/en not_active Expired
- 1974-05-15 DE DE2423529A patent/DE2423529A1/de active Pending
- 1974-05-15 US US05/469,954 patent/US3961060A/en not_active Expired - Lifetime
- 1974-05-16 JP JP49053962A patent/JPS5029716A/ja active Pending
- 1974-05-16 FI FI1520/74A patent/FI152074A7/fi unknown
- 1974-05-16 FR FR7417124A patent/FR2229412A1/fr not_active Withdrawn
- 1974-05-17 NL NL7406689A patent/NL7406689A/xx unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004501888A (ja) * | 2000-06-23 | 2004-01-22 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | ホスホジエステラーゼｉｖ阻害活性を有する薬剤の調製に有用な化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6889274A (en) | 1975-11-20 |
| DE2423529A1 (de) | 1974-12-05 |
| FR2229412A1 (enExample) | 1974-12-13 |
| US3961060A (en) | 1976-06-01 |
| NL7406689A (enExample) | 1974-11-19 |
| FI152074A7 (enExample) | 1974-11-18 |